Ikaria

Results: 71



#Item
51Nitric oxide / Vasodilation / Portopulmonary hypertension / Iloprost / Chemistry / Hypertension / Pulmonary hypertension

FDA GRANTS ORPHAN DRUG DESIGNATION TO IKARIA® FOR USE OF INHALED NITRIC OXIDE IN PULMONARY ARTERIAL HYPERTENSION -- Investigational New Drug Application Submitted -- Hampton, NJ – January 23, 2012 – Ikaria, Inc., a

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2012-01-30 17:01:52
52Hypertension / Intensive care medicine / Nitrogen metabolism / Pulmonary hypertension / Nitric oxide / Neonatal intensive care unit / Medicine / Health / Chemistry

IKARIA® LAUNCHES NEXT-GENERATION DRUG-DELIVERY SYSTEM --Third-generation INOMAX DSIR Utilizes Infrared Technology -Clinton, NJ, April 11, 2011 – Ikaria, Inc., a critical care company focused on developing and commerci

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-08-30 10:08:18
53Icaria / Pharmaceutical industry / Technology / Pharmacology / Pharmaceutical sciences / GlaxoSmithKline / Avaya

CONTACTS Matthew Bennett Ikaria[removed]removed] Jason Rando

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-06-28 11:52:54
54Pediatrics / Intensive care medicine / Nitrogen metabolism / Neonatal intensive care unit / Nursing / Preterm birth / Nitric oxide / Hydrogen sulfide / Bronchopulmonary dysplasia / Chemistry / Medicine / Health

INHALED NITRIC OXIDE DATA PRESENTED AT EUROPEAN ACADEMY OF PEDIATRICS MEETING Clinton, NJ, October 25, 2008– Ikaria Holdings, Inc. today announced that results from its Phase III clinical trial - INOT27, nitric oxide f

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-06-28 11:52:50
55Nitrogen metabolism / Pulmonary hypertension / Nitric oxide / Hepatorenal syndrome / Medicine / Chemistry / Health / Hypertension

IKARIA® TO PRESENT AT 14TH ANNUAL BIO CEO & INVESTOR CONFERENCE Hampton, NJ, February 6, 2012 – Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2012-04-04 15:36:13
56Pollutants / Smog / Intensive care medicine / Extracorporeal membrane oxygenation / Nitric oxide / Hydrogen sulfide / Nitrogen dioxide / Pulmonary hypertension / NOx / Chemistry / Oxides / Free radicals

CONTACTS Matthew Bennett Ikaria[removed]removed]

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-06-28 11:52:53
57Smog / Nitrogen metabolism / Neurotransmitters / Nitric oxide / Ikaria / Nitrogen dioxide / NOx / Chemistry / Oxides / Free radicals

IKARIA® TO PRESENT AT 27th ANNUAL JPMORGAN HEALTHCARE CONFERENCE Clinton, NJ, January 8, 2008 – Ikaria Holdings, Inc. today announced that its President & CEO, Daniel Tassé, will present at the 27th Annual JPMorgan H

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-06-28 11:52:58
58Ikaria / Hepatorenal syndrome / Syndromes / Wedbush Securities

IKARIA® TO PRESENT AT 2011 WEDBUSH LIFE SCIENCES MANAGEMENT ACCESS CONFERENCE Hampton, NJ, August 9, 2011 – Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-08-30 10:08:20
59Clinical research / Neurotransmitters / Nitric oxide / Nitrogen metabolism / Oxides / Pulmonary hypertension / Food and Drug Administration / King Pharmaceuticals / Chemistry / Pharmaceutical sciences / Hypertension

IKARIA® APPOINTS CHIEF MEDICAL OFFICER Hampton, NJ, April 11, 2012 – Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced th

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2012-05-29 13:53:19
60Hepatorenal syndrome / Syndromes / Hepatology / Membrane technology / Peptides / Cirrhosis / Vasopressin / Hemodialysis / Terlipressin / Medicine / Biology / Health

IKARIA® BEGINS ENROLLMENT OF PIVOTAL TRIAL FOR LUCASSIN® Clinton, NJ, November 30, 2010 – Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). T

Add to Reading List

Source URL: www.ikaria.com

Language: English - Date: 2011-06-28 11:53:05
UPDATE